Chardan Capital reissued their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY - Free Report) in a research report sent to investors on Friday, Benzinga reports. The brokerage currently has a $225.00 price target on the biopharmaceutical company's stock.
Other equities analysts also recently issued research reports about the company. BMO Capital Markets reiterated an outperform rating and issued a $234.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 27th. Needham & Company LLC reissued a buy rating and issued a $200.00 price objective on shares of Alnylam Pharmaceuticals in a report on Thursday. The Goldman Sachs Group downgraded shares of Alnylam Pharmaceuticals from a buy rating to a neutral rating and dropped their price objective for the company from $230.00 to $173.00 in a report on Friday, February 16th. Citigroup cut their target price on shares of Alnylam Pharmaceuticals from $237.00 to $227.00 and set a buy rating for the company in a research report on Friday, February 16th. Finally, William Blair restated an outperform rating on shares of Alnylam Pharmaceuticals in a research note on Monday, April 8th. Seven investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of Moderate Buy and an average price target of $215.88.
Check Out Our Latest Research Report on Alnylam Pharmaceuticals
Alnylam Pharmaceuticals Stock Up 1.3 %
ALNY stock traded up $2.02 during midday trading on Friday, hitting $152.33. The company's stock had a trading volume of 452,157 shares, compared to its average volume of 763,489. Alnylam Pharmaceuticals has a 1 year low of $141.98 and a 1 year high of $218.88. The stock has a market cap of $19.19 billion, a price-to-earnings ratio of -42.22 and a beta of 0.41. The stock's 50-day moving average price is $149.76 and its 200 day moving average price is $165.25.
Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.23. The company had revenue of $494.33 million for the quarter, compared to the consensus estimate of $428.01 million. Alnylam Pharmaceuticals's quarterly revenue was up 54.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.40) EPS. As a group, equities analysts forecast that Alnylam Pharmaceuticals will post -4.46 earnings per share for the current fiscal year.
Institutional Trading of Alnylam Pharmaceuticals
Several institutional investors and hedge funds have recently modified their holdings of the business. Allspring Global Investments Holdings LLC grew its holdings in shares of Alnylam Pharmaceuticals by 572.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 143 shares in the last quarter. Quent Capital LLC lifted its position in Alnylam Pharmaceuticals by 246.0% during the fourth quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company's stock valued at $33,000 after purchasing an additional 123 shares during the last quarter. Anchor Investment Management LLC purchased a new position in Alnylam Pharmaceuticals in the 4th quarter worth approximately $38,000. Robeco Institutional Asset Management B.V. increased its holdings in shares of Alnylam Pharmaceuticals by 155.7% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company's stock worth $39,000 after buying an additional 12,513 shares during the last quarter. Finally, GAMMA Investing LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at $52,000. Hedge funds and other institutional investors own 92.97% of the company's stock.
About Alnylam Pharmaceuticals
(
Get Free Report)
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
Further Reading
Before you consider Alnylam Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alnylam Pharmaceuticals wasn't on the list.
While Alnylam Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
